title: Chemoprevention of prostate cancer.
abstract: Over the past two decades, many more men are diagnosed with prostate cancer then die of the disease. This increase in diagnosis has led to aggressive treatment of indolent disease in many individuals and has been the impetus for finding a means of reducing the risk of prostate cancer. In the past decade, there have been eight large trials of prostate cancer risk reduction using dietary supplements, 5α-reductase inhibitors, or anti-estrogens. The only two trials which have demonstrated efficacy are those involving 5α-reductase inhibitors: the PCPT (finasteride) and REDUCE (dutasteride). This review examines prostate cancer risk reduction, with emphasis on conclusions that can be drawn from these two landmark studies.
authors: Oncology Clinical Development, GlaxoSmithKline Inc., 5 Moore Drive, Research Triangle Park, NC 27709, USA. roger.s.rittmaster@gsk.com
authors: Roger S
authors: RS
authors: Rittmaster